AbbVie’s assertion of Rinvoq patent thicket echoes Humira disputes strategy

AbbVie’s assertion of Rinvoq patent thicket echoes Humira disputes strategy

Recent lawsuits demonstrate that large pharma patent estates are not limited to biosimilar disputes

Unlock unlimited access to all IAM content